Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High
Biodefense Stocks Sector Snapshot; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX ), (NasdaqGM: SIGA)
Category: Investment, Biotech, Biodefense
Ideas get bigger when you share them...
Visit this company: www.aethlonmedical.com
Point Roberts, WA - April 14, 2011 - Investorideas.com, a leader in sector stock research including biotech and biodefense stocks issues a trading alert on Emergent Biosolutions, Inc. (NYSE: EBS) as it hit a 52 week high in Wednesday’s trading. The Company reported its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress.
Biotech/ Biodefense Stocks Sector Snapshot ( as of close April 14 th)
- Aethlon Medical (OTCBB: AEMD) closed at $0.1036 on over 242,000 shares, with its 52 week range of $0.096 - 0.35
- Dynasil Corporation (NASDAQ GM: DYSL) ended at $4.14, with a 52 week range of $ 2.35 - 7.48
- Emergent Biosolutions, Inc. (NYSE: EBS ) closed at $24,68 hitting its 52 week high; $14.11 - 25.24
- PharmAthene, Inc. (NYSE Amex: PIP) finished trading at $3.17, its 52 week range of $1.25 - 4.96
- Protalix BioTherapeutics, Inc. (AMEX: PLX ) closed at $7.24, up 0.15 (2.12%)
- Siga Technologies (NasdaqGM: SIGA ) ended trading at $13.4, up 0.48 (3.71%) on over 437,000 shares
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
ROCKVILLE, Md.--- Emergent BioSolutions Inc. (NYSE: EBS ) announced that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals and companies in the global vaccine industry.
"This award is a testament to the collective efforts of the Emergent BioSolutions team, who on a daily basis and all over the world, lives out the corporate mission – to protect life,” said Mr. El-Hibri. "Our team shares a passion and commitment to make vital contributions to address unmet and underserved medical needs. It is an honor to be recognized for the work that we do.”
In selecting the winner for this category, the distinguished panel of judges evaluated the finalists based on their commitment to disease prevention and treatment, leadership, contribution to company performance, communication, and vision, industry influence, and achievements in company positioning and status.
Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation
SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.
Full news: http://www.investorideas.com/CO/AEMD/news/2011/04121.asp
Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD),
Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
James A. Joyce
Visit the Aethlon Medical (OTCBB: AEMD) showcase page on Investorideas.com
Get added to the company's news alerts:
Emergent Biosolutions, Inc. (NYSE: EBS )
Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. www.emergentbiosolutions.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more Biodfense stocks at Investorideas.com
Research Biotech Stocks atInvestorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
800-665-0411 - firstname.lastname@example.org
Source - Investorideas.com
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers (175 top energy news).
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp